Patients with cancer that is not strictly terminal often suffer needless pain.' To combat this many clinicians use complex methods of pain control and may choose intramuscular or intravenous routes of administration in preference to drugs given by mouth. Use of epidural analgesia is on the increase in patients with cancer, and some have even been treated by cerebral intraventricular routes.
Certainly patients with severe acute pain may be given rapid relief by parenteral analgesics, with useful sedation of short duration2; and prolonged effects may be achieved by continuous infusion.3 Nevertheless, the chronic pain of cancer requires longlasting analgesia without sedation by the simplest method possible,4 and in these circumstances oral medication has considerable advantages [5] [6] [7] Morphine mixtures remain popular since they were introduced in 1896,8 but the diversity of their contents is rivalled only by the variety of their names. The constituents of the "Brompton cocktail" are protean,9 and the magical connotation of mist euphoria and the macabre implications of mist mortis hint at the myths surrounding all opiates. Nevertheless, morphine and diamorphine are frequently the oral narcotics of choice. But do they work fast? How should they be prescribed ? Is the addition of cocaine advantageous ?
Morphine and its semisynthetic derivative diamorphine remain the most widely used analgesics for the control of severe pain in patients with cancer in Britain and both are effective by mouth. Diamorphine is highly soluble (100 mg dissolves in 0-2 ml of water) and is more rapidly and more completely absorbed than morphine,10 thus providing faster analgesia of slightly shorter duration.1" Morphine is half as potent as diamorphine but equally efficaceous, and because diamorphine is rapidly deacetylated to morphine and monoacetylmorphine in vivo it has similar effects to morphine itself in terms both ofanalgesia and ofside effects. Continuous dosage in patients with cancer gives higher blood concentrations than expected from single dose studies in normal people.12 Diamorphine is also more lipid soluble and after intravenous administration may cross the blood-brain barrier to cause the traditional "high" described by heroin addicts. This has not been described in cancer sufferers after oral administration.
Morphine and diamorphine should be prescribed as a simple elixir in water or chloroform water with no additives.13 There is no standard dose: the concentration must be individually adjusted to the requirements of each patient. Tradii) BRITISH MEDICAL JOURNAL 1983. All reproduction rights reserved.
tional compound mixtures in a sweetened alcoholic base may burn the mouth and oesophagus in susceptible patients and are frequently too sweet for those -with disordered taste, while their shelf life is short. By contrast, unbuffered morphine and diamorphine in tap water or chloroform water at room temperature have a shelf life of about a month,14 degrading by only 10%,, to monoacetylmorphine. Such a rate of degradation is unimportant in traditional prescribing. Patients receiving a dose of diamorphine of over 20 mg four hourly will require a separate non-sedative antiemetic. Below this dose antiemetics need be used only if nausea occurs. Furthermore, since all patients taking narcotic analgesics become constipated, a routine laxative combining a stool softener with a peristaltic agent is always required. Cocaine no longer has any place in analgesic mixtures. It neither raises the mood, relieves depression, nor prevents drowsiness, and in the elderly it may cause restlessness, agitation, and confusion. Pain clinics and hospices specialising in relieving the pain of cancer use oral morphine and diamorphine effectively, safely, and with few side effects. The techniques can be learnt easily. Yet in district general hospitals the use of parenteral analgesia is commonplace in similar patients without the three indications for injection, infusion, or by suppository: persistent vomiting, overwhelming pain, and an inability to swallow.
Oral mixtures are cheap, easy to use, effective, and safe. Why are they not used more? E R HILLIER Primary aldosteronism: how hard should we look?
Priorities may sometimes be decided quite innocently for the wrong reasons-and especially when the conceptually attractive competes with the unknown. Among the large section of the population at risk from high blood pressure only a small proportion will have a definable cause and the remainder are classified as having essential hypertension. Though both genetic and environmental influences are undoubtedly at work in these patients, no single cause can be found as yet-nor is it likely that any ever will be. The maxim "first seek a cause" is not absolute. A more relevant question is "how hard should I look ?" The answer to this question should be determined on the one hand by the benefits to the patient and on the other by the ease with which a cause can be detected. With the most common detectable cause of hypertension the search is so simple that it should be carried out in every case: any woman of childbearing age should be asked whether she is taking the contraceptive pill. With renal and endocrine causes of hypertension, where the difficulty of making the diagnosis is greater, cost and benefit have to be weighed more carefully. We have to define the population we are investigating. Who is more likely to have a primary cause ? What are the dangers of a misdiagnosis ? Are certain patients likely to benefit particularly if the diagnosis is made in them? In other words, though understanding the physiology and pathology of these conditions may help us to construct appropriate investigations and treatments, when planning what to do for an individual patient in an imperfect world with limited resources we have to start by analysing patient benefit. This is rather easier to do with renovascular hypertension1 2 than with primary aldosteronism, which is much rarer. Nevertheless some questions can be answered.
We do not know the overall incidence of primary aldosteronism. It is certainly less common than was originally postulated.3 The incidence is probably less than 1%,4 5though the more intensively primary aldosteronism is sought the more often it is encountered, and, like other forms of secondary hypertension, it is much more frequently encountered in specialist clinics than in unselected populations. The cardinal manifestations are a reduced serum potassium concentration, associated with raised plasma and urinary concentrations of aldosterone together with suppressed plasma renin activity. Suspicion is raised in most cases by a low serum potassium concentration, though this is more commonly a manifestation of secondary aldosteronism. Nevertheless, among 80 patients diagnosed at the Cleveland Clinic as having primary aldosteronism, no fewer than 22 had a normal serum potassium concentration at the time and 29 had plasma renin activities which were stimulated into the normal range by a low salt diet.6 The proportion of misdiagnoses falls with repeated measurement, though in one large series 1 1 0% of patients were persistently normokalaemic despite multiple measurements of serum potassium concentrations.5
By measuring either potassium or renin we seem likely, therefore, to miss a substantial number of patients with primary aldosteronism. Does it matter? The risks of primary aldosteronism are due to hypertension and potassium depletion. Since in most patients (though by no means all6) the raised blood pressure can be controlled with medication the most important clinical problem in primary aldosteronism is potassium depletion. Apart from causing unpleasant symptoms such as muscular weakness, hypokalaemia may be sufficiently severe to cause life threatening arrhythmias. Even more modest degrees of hypokalaemia may not be as innocent as was once thought.7 Hypokalaemia can usually be controlled by potassium retaining diuretics,8-10 but a relatively straightforward surgical procedure such as removal of an adenoma producing aldosterone has clear advantages provided it carries a high likelihood of success.
Unfortunately for our decision making process, the matter is not as simple as this analysis suggests. Firstly, primary aldosteronism is not a homogeneous condition. About 400/0 of patients have bilateral adrenal nodular hyperplasia rather than an adenoma producing aldosterone.6 These patients are best treated medically8; indeed, there are good physiological grounds for believing that nodular hyperplasia represents a form of essential hypertension in which the adrenal cortex is particularly sensitive to the action of angiotensin II in stimulating aldosterone secretion.'1 12 The other clinically relevant fact about this group is that the biochemical changes tend to be less florid than in patients with adenomas, though there is considerable overlap between groups unless an elaborate statistical analysis is made of several variables5; even then it is difficult to apply such analysis to biochemical values obtained in different laboratories.
When, therefore, we investigate patients with normal or borderline serum potassium concentrations we may very well find that any primary aldosteronism we detect will be of a type which is best treated medically. If we insist on being reasonably sure that the diagnosis has not been missed we shall have to use intensive investigation requiring measurement of the aldosterone response to such procedures as dietary salt restriction and upright posture.6 The harder we look the more patients with aldosteronism we are likely to find, though the yield in terms of disorder correctable by surgery is likely to decline spectacularly the more widely we cast our net. If the dividing line between essential hypertension and primary aldosteronism due to nodular hyperplasia is as arbitrary as now appears likely we can no more expect to find an acid test for primary aldosteronism than for essential hypertension. In these circumstances screening for primary aldosteronism becomes pragmatic, and guidance should be based on likely outcome.
What guidance can be offered? Persistent severe hypokalaemia (serum potassium <3 0 mmol(mEq)/l) occurring in either treated or untreated hypertensive patients requires investigation unless possible surgery is contraindicated on other grounds. Milder hypokalaemia (serum potassium 3.O-3-5 mmol/l) in untreated patients is also probably worth investigating. Substantially fewer benefits are likely from
